i don't think it is likely that Naltrexone will be helpful with CBT. here is a negative study that may be of interest:
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study
Amiaz R, Fostick L, Gershon A, Zohar J; European Neuropsychopharmacology 2008; 18 (6); 455-461. [Epub 2008 Mar 18]
if you want to use a medication that might speed up CBT, you could try cycloserine which has been studied with some positive effects. here is a reference from our group:
Am J Psychiatry. 2008 Mar;165(3):335-41; quiz 409. Epub 2008 Feb 1.
Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive
Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro
P, Jenike MA, Rauch SL.
Obsessive-Compulsive Disorder Clinic, Department of Psychiatry, Massachusetts
General Hospital, Boston, MA 02114, USA. firstname.lastname@example.org
Am J Psychiatry. 2008 Aug;165(8):1050. Am J Psychiatry. 2008 Mar;165(3):293-6.
OBJECTIVE: This study examined whether d-cycloserine, a partial agonist at the
N-methyl-D-aspartate (NMDA) glutamatergic receptor, enhances the efficacy of
behavior therapy for obsessive-compulsive disorder (OCD). METHOD: A randomized,
double-blind, placebo-controlled trial investigating D-cycloserine versus placebo
augmentation of behavior therapy was conducted in 23 OCD patients. Patients first
underwent a diagnostic interview and pretreatment evaluation, followed by a
psychoeducational/treatment planning session. Then they received 10 behavior
therapy sessions. Treatment sessions were conducted twice per week. One hour
before each of the behavior therapy sessions, the participants received either
D-cycloserine, 100 mg, or a placebo. RESULTS: Relative to the placebo group, the
D-cycloserine group's OCD symptoms were significantly more improved at
mid-treatment, and the D-cycloserine group's depressive symptoms were
significantly more improved at posttreatment. CONCLUSIONS: These data provide
support for the use of D-cycloserine as an augmentation of behavior therapy for
OCD and extend findings in animals and other human disorders suggesting that
behavior therapy acts by way of long-term potentiation of glutamatergic pathways
and that the effects of behavior therapy are potentiated by an NMDA agonist.